Markham C. Luke

489 total citations
25 papers, 328 citations indexed

About

Markham C. Luke is a scholar working on Pediatrics, Perinatology and Child Health, Pulmonary and Respiratory Medicine and Pharmaceutical Science. According to data from OpenAlex, Markham C. Luke has authored 25 papers receiving a total of 328 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pediatrics, Perinatology and Child Health, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Pharmaceutical Science. Recurrent topics in Markham C. Luke's work include Pharmaceutical studies and practices (7 papers), Inhalation and Respiratory Drug Delivery (5 papers) and Pharmaceutical Economics and Policy (5 papers). Markham C. Luke is often cited by papers focused on Pharmaceutical studies and practices (7 papers), Inhalation and Respiratory Drug Delivery (5 papers) and Pharmaceutical Economics and Policy (5 papers). Markham C. Luke collaborates with scholars based in United States, India and South Korea. Markham C. Luke's co-authors include Donald S. Coffey, Gavril W. Pasternak, Charles E. Inturrisi, Byron C. Yoburn, Sam G. Raney, Maureen Price, Elliot F. Hahn, Beth Solomon, Kim B. Yancey and Giovana R. Thomas and has published in prestigious journals such as PEDIATRICS, Advanced Drug Delivery Reviews and Journal of Controlled Release.

In The Last Decade

Markham C. Luke

23 papers receiving 320 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Markham C. Luke United States 9 91 72 68 62 62 25 328
Wu Deng United States 11 154 1.7× 33 0.5× 28 0.4× 47 0.8× 22 0.4× 18 294
Masahiro Fujii Japan 12 132 1.5× 35 0.5× 82 1.2× 61 1.0× 43 0.7× 52 449
Dimitra Kalavrizioti Greece 11 88 1.0× 13 0.2× 34 0.5× 43 0.7× 41 0.7× 22 320
Eric Shin United States 8 115 1.3× 12 0.2× 27 0.4× 35 0.6× 25 0.4× 12 315
Poorva Jain United States 9 103 1.1× 23 0.3× 20 0.3× 11 0.2× 24 0.4× 13 296
Hina Khan United States 11 145 1.6× 17 0.2× 24 0.4× 15 0.2× 13 0.2× 45 368
Yoichi Yoshida Japan 10 125 1.4× 20 0.3× 25 0.4× 16 0.3× 9 0.1× 46 332
Jingping Xu China 10 155 1.7× 35 0.5× 38 0.6× 22 0.4× 14 0.2× 20 435
Yanfei Li China 12 118 1.3× 10 0.1× 20 0.3× 138 2.2× 31 0.5× 43 417

Countries citing papers authored by Markham C. Luke

Since Specialization
Citations

This map shows the geographic impact of Markham C. Luke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markham C. Luke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markham C. Luke more than expected).

Fields of papers citing papers by Markham C. Luke

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markham C. Luke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markham C. Luke. The network helps show where Markham C. Luke may publish in the future.

Co-authorship network of co-authors of Markham C. Luke

This figure shows the co-authorship network connecting the top 25 collaborators of Markham C. Luke. A scholar is included among the top collaborators of Markham C. Luke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markham C. Luke. Markham C. Luke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tu, Dandan, Jacob Riseman, Markham C. Luke, et al.. (2025). Improved Dual-Modality Bioequivalence Evaluation of Topical Formulations Within Human Skin Using Stimulated Raman Scattering Microscopy. Pharmaceutics. 17(9). 1193–1193.
2.
Luke, Markham C.. (2024). Locally acting dermatology drug products: Pharmaco-analytic considerations for bioequivalence. European Journal of Pharmaceutical Sciences. 199. 106815–106815.
3.
Tu, Dandan, Isaac J. Pence, Priyanka Ghosh, et al.. (2024). Determining topical product bioequivalence with stimulated Raman scattering microscopy. Journal of Controlled Release. 367. 864–876. 8 indexed citations
4.
Kim, Donggyu, Joongho Ahn, Dong‐Hyun Kim, et al.. (2024). Quantitative volumetric photoacoustic assessment of vasoconstriction by topical corticosteroid application in mice skin. Photoacoustics. 40. 100658–100658. 9 indexed citations
5.
Fang, Lanyan, Rajanikanth Madabushi, Hao Zhu, et al.. (2024). Narrow Therapeutic Index Drugs: FDA Experience, Views, and Operations. Clinical Pharmacology & Therapeutics. 117(1). 116–129. 3 indexed citations
6.
7.
Wang, Zhong, et al.. (2022). Medication Cost-Savings and Utilization of Generic Inhaled Corticosteroid (ICS) and Long-Acting Beta-Agonist (LABA) Drug Products in the USA. Therapeutic Innovation & Regulatory Science. 56(2). 346–357. 5 indexed citations
8.
Newman, Bryan, Andrew Babiskin, Elizabeth Bielski, et al.. (2022). Scientific and regulatory activities initiated by the U.S. Food and drug administration to foster approvals of generic dry powder inhalers: Bioequivalence perspective. Advanced Drug Delivery Reviews. 190. 114526–114526. 12 indexed citations
9.
El‐Gendy, Nashwa, Craig M. Bertha, Andrew Babiskin, et al.. (2022). Scientific and regulatory activities initiated by the U.S. food and drug administration to foster approvals of generic dry powder inhalers: Quality perspective. Advanced Drug Delivery Reviews. 189. 114519–114519. 11 indexed citations
10.
Ghosh, Priyanka, Sam G. Raney, & Markham C. Luke. (2022). How Does the Food and Drug Administration Approve Topical Generic Drugs Applied to the Skin?. Dermatologic Clinics. 40(3). 279–287. 7 indexed citations
11.
Ghosh, Priyanka, Sam G. Raney, & Markham C. Luke. (2021). Evaluation of cutaneous pharmacokinetics: the past, the present and the future. 2 indexed citations
12.
Luke, Markham C. & Darby Kozak. (2020). Regulating Generic Ophthalmologic Drug Bioequivalence—Envisioning Accessibility for Patients. Journal of Ocular Pharmacology and Therapeutics. 37(3). 157–161. 5 indexed citations
13.
Raney, Sam G. & Markham C. Luke. (2020). A new paradigm for topical generic drug products: Impact on therapeutic access. Journal of the American Academy of Dermatology. 82(6). 1570–1571. 13 indexed citations
14.
Kwa, Michael, Kyle Tegtmeyer, Leah J. Welty, et al.. (2020). The relationship between the number of available therapeutic options and government payer (medicare part D) spending on topical drug products. Archives of Dermatological Research. 312(8). 559–565. 5 indexed citations
15.
16.
Luke, Markham C., Thomas N. Darling, Ronald M. Summers, et al.. (1999). Mucosal Morbidity in Patients With Epidermolysis Bullosa Acquisita. Archives of Dermatology. 135(8). 954–9. 58 indexed citations
17.
Schiro, James A., Susan B. Mallory, Laurie Demmer, S. Bruce Dowton, & Markham C. Luke. (1996). Grouped papules in Hurler-Scheie syndrome. Journal of the American Academy of Dermatology. 35(5). 868–870. 6 indexed citations
18.
Luke, Markham C. & Donald S. Coffey. (1994). Human Androgen Receptor Binding to the Androgen Response Element of Prostate Specific Antigen. Journal of Andrology. 15(1). 41–51. 74 indexed citations
19.
Yoburn, Byron C., Markham C. Luke, Gavril W. Pasternak, & Charles E. Inturrisi. (1988). Upregulation of opioid receptor subtypes correlates with potency changes of morphine and dadle. Life Sciences. 43(16). 1319–1324. 52 indexed citations
20.
Luke, Markham C., Elliot F. Hahn, Maureen Price, & Gavril W. Pasternak. (1988). Irreversible opiate agonists and antagonists: V. Hydrazone and acylhydrazone derivatives of naltrexone. Life Sciences. 43(15). 1249–1256. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wu Deng Breakdown of academic impact, for papers by Masahiro Fujii Breakdown of academic impact, for papers by Dimitra Kalavrizioti Breakdown of academic impact, for papers by Eric Shin Breakdown of academic impact, for papers by Poorva Jain Breakdown of academic impact, for papers by Hina Khan Breakdown of academic impact, for papers by Yoichi Yoshida Breakdown of academic impact, for papers by Jingping Xu Breakdown of academic impact, for papers by Yanfei Li
Rankless by CCL
2026